The CooperCOO +0.28%84 Debt-to-EBITDA is 9.06 as of Apr. 2026, which is 264% above its 10-year median of 2.49. GuruFocus rates COO with a GF Score™ of 84/100 and a GF Value™ of $101.17 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 470 Medical Devices & Instruments companies, The Cooper ranks worse than 67.02% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for The Cooper's Debt-to-EBITDA or its related term are showing as below:
COO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.8 Med: 2.49 Max: 3.5
Current: 2.76
During the past 13 years, the highest Debt-to-EBITDA Ratio of The Cooper was 3.50. The lowest was 1.80. And the median was 2.49.
COO's Debt-to-EBITDA is ranked worse than 67.02% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs COO: 2.76
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The Cooper Debt-to-EBITDA Related Terms
The Cooper Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for The Cooper's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, The Cooper's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where The Cooper's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.
The Cooper (COO) has a Debt-to-EBITDA of 9.06 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on The Cooper. This is 264% above median its historical median of 2.49. Over the past decade, The Cooper's Debt-to-EBITDA has ranged from 1.80 to 3.50. According to the industry distribution chart, The Cooper ranks #315 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 67%.
Is The Cooper's Debt-to-EBITDA too high?
The Cooper's current Debt-to-EBITDA of 9.06 is 264% above median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 3.50. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. The Cooper's value of 9.06 is 471.6% above this industry median. Based on the distribution chart, The Cooper ranks #315 out of 470 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, The Cooper has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Debt-to-EBITDA compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #315 out of 470 companies for Debt-to-EBITDA. This places The Cooper in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. The Cooper's value of 9.06 is 471.6% above this benchmark. Historically, The Cooper's own Debt-to-EBITDA has ranged from 1.80 to 3.50 over the past decade. While the company's 10-year median is 2.49 vs. the industry median of 1.59, The Cooper has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current Debt-to-EBITDA of 9.06 is 471.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on The Cooper. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Debt-to-EBITDA is 9.06, which is 264% above median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $101.17, compared to a current price of $70.90 — trading 29.9% below its estimated fair value. The current Debt-to-EBITDA is 9.06, which is 264% above median its 10-year median of 2.49 and 471.6% above the Medical Devices & Instruments industry median of 1.59. The Cooper's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For The Cooper (COO), the current Debt-to-EBITDA is 9.06 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $70.90 is trading 29.9% below its estimated GF Value™ of $101.17.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
Debt-to-EBITDA: 9.06 (264% above median its 10-year median of 2.49)
GF Value™: $101.17 vs. price of $70.90 (29.9% below fair value)
Industry Position: 471.6% above the Medical Devices & Instruments median (#315 of 470)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
84GF Score
Get the complete analysis for COO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
